John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$474M |
| 2 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$357M |
| 3 |
Accenture
ACN
|
+$246M |
| 4 |
Advanced Micro Devices
AMD
|
+$235M |
| 5 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$231M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$381M |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$375M |
| 3 |
iShares Expanded Tech-Software Sector ETF
IGV
|
+$348M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$292M |
| 5 |
Snowflake
SNOW
|
+$258M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.18% |
| 2 | Financials | 15.54% |
| 3 | Industrials | 10.5% |
| 4 | Healthcare | 9.8% |
| 5 | Consumer Discretionary | 8.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DMRA
3426
Damora Therapeutics
DMRA
$1.91B
| $75.5K | ﹤0.01% |
+20,296
| New | +$68.7K |
|
3427
Pulmonx
LUNG
$97.9M
| $75.3K | ﹤0.01% |
46,456
+15,557
| +50% | +$32.5K |
|
|
BTLN
3428
Brightline Interactive
BTLN
$21.9M
| $74.2K | ﹤0.01% |
45,268
+7,340
| +19% | +$10.9K |
|
3429
Xilio Therapeutics
XLO
$60.4M
| $74K | ﹤0.01% |
6,271
+697
| +13% | +$6.98K |
|
|
YARW
3430
Yarrow Bioscience
YARW
$108M
| $74K | ﹤0.01% |
+4,416
| New | +$144K |
|
|
MYSE
3431
Myseum.AI Inc
MYSE
$14.1M
| $71.6K | ﹤0.01% |
31,679
+12,822
| +68% | +$29.3K |
|
3432
Galectin Therapeutics
GALT
$391M
| $70.5K | ﹤0.01% |
+16,647
| New | +$62.6K |
|
|
OKUR
3433
OnKure Therapeutics
OKUR
$164M
| $69.9K | ﹤0.01% |
25,435
-427
| -2% | -$1.06K |
|
3434
Lantern Pharma
LTRN
$28.1M
| $69.8K | ﹤0.01% |
+16,041
| New | +$67K |
|
|
DEFT
3435
Defi Technologies
DEFT
$243M
| $69.6K | ﹤0.01% |
32,969
-268,256
| -89% | -$694K |
|
3436
KVH Industries
KVHI
$137M
| $69.2K | ﹤0.01% |
12,363
-7,450
| -38% | -$41.4K |
|
|
SONN
3437
DELISTED
Sonnet BioTherapeutics
SONN
| $68.6K | ﹤0.01% |
+14,972
| New | +$66.4K |
|
3438
Koss Corp
KOSS
$33.3M
| $67.8K | ﹤0.01% |
+13,355
| New | +$75.6K |
|
|
VIVS
3439
VivoSim Labs
VIVS
$3.95M
| $67.7K | ﹤0.01% |
+23,192
| New | +$54.9K |
|
3440
Twin Vee PowerCats
VEEE
$5.83M
| $66.8K | ﹤0.01% |
+659
| New | +$55.9K |
|
|
ABX
3441
Abacus Global Management
ABX
$933M
| $65.1K | ﹤0.01% |
11,368
-65,223
| -85% | -$387K |
|
|
NOTE
3442
DELISTED
FiscalNote
NOTE
| $64.3K | ﹤0.01% |
+13,887
| New | +$89.8K |
|
|
EPIX
3443
DELISTED
ESSA Pharma
EPIX
| $64.2K | ﹤0.01% |
336,164
+113,837
| +51% | +$136K |
|
3444
Pangaea Logistics
PANL
$534M
| $63.3K | ﹤0.01% |
+12,451
| New | +$64.4K |
|
3445
Q32 Bio
QTTB
$489M
| $62.4K | ﹤0.01% |
+31,506
| New | +$60.5K |
|
3446
MIRA Pharmaceuticals
MIRA
$33.6M
| $62.2K | ﹤0.01% |
45,703
+25,816
| +130% | +$37.5K |
|
3447
BioVie
BIVI
$16.7M
| $61.8K | ﹤0.01% |
+32,505
| New | +$132K |
|
3448
LivePerson
LPSN
$34.1M
| $60.7K | ﹤0.01% |
6,932
-29,151
| -81% | -$410K |
|
3449
Coherus Oncology
CHRS
$216M
| $58.6K | ﹤0.01% |
+35,712
| New | +$39.7K |
|
|
ARTV
3450
Artiva Biotherapeutics
ARTV
$560M
| $58.4K | ﹤0.01% |
20,364
-1,007
| -5% | -$2.69K |
|
Similar funds
John Overdeck's Q3 2025 Portfolio in Review
As of Q3 2025, John Overdeck held 4,027 positions worth $67.2B, up 19% from $56.5B the previous quarter. Its ten largest holdings account for 6.2% of the portfolio.
John Overdeck deployed $4.46B of net new capital in Q3 2025, opening 877 new positions and adding to 1,461 existing holdings. Its largest new stake was Berkshire Hathaway Class B: 379,096 shares worth $191M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $381M trimmed.
- John Overdeck's largest Q3 2025 buy was Berkshire Hathaway Class B: 379,096 shares worth $191M.
- John Overdeck added most to State Street Financial Select Sector SPDR ETF in Q3 2025, an estimated $474M increase.
- John Overdeck's biggest Q3 2025 reduction was Invesco QQQ Trust, cutting an estimated $381M.
- John Overdeck fully exited NextEra Energy, Inc. 6.926% Corporate Units in Q3 2025, selling an estimated $115M.
- John Overdeck's ten largest holdings make up 6.2% of its $67.2B portfolio in Q3 2025.
- John Overdeck opened 877 new positions and closed 399 in Q3 2025.
- John Overdeck's portfolio value rose 19% quarter-over-quarter to $67.2B.
Based on Two Sigma Investments's 13F filing for Q3 2025, filed 14 Nov 2025.